Brief: Paion AG Reports Positive Remimazolam Topline Data In EU Phase III Trial In General Anesthesia
19/11/2020 21:48
Nov 19 (Reuters) - Paion AG PA8G.DE :
* PAION REPORTS POSITIVE REMIMAZOLAM TOPLINE DATA IN EU
PHASE III
TRIAL IN GENERAL ANESTHESIA
* PRIMARY ENDPOINT MET: REMIMAZOLAM DEMONSTRATED
NON-INFERIORITY
TO PROPOFOL FOR ANESTHETIC EFFECT
* KEY SECONDARY ENDPOINT MET: REMIMAZOLAM DEMONSTRATED
SUPERIOR
HEMODYNAMIC STABILITY COMPARED TO PROPOFOL
* EU PHASE III PROGRAM COMPLETED; DATA TO SERVE AS BASIS FOR
MAA
SUBMISSION IN GENERAL ANESTHESIA
Source text for Eikon: ID:nEQ4xRKcba
Further company coverage: PA8G.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022